Skip to main content
Signal8

Imugene Limited (IUGNF)

Sector: Biotechnology

Industry: Biotechnology

Imugene Limited logo

Imugene Limited

OTC:IUGNFHealthcare
-22.77%$0.0290
CLOSED
Mkt Cap$15.94M
EV-
Float312.07M
O/S549.58M
VOL588 sh
$ Vol$17
RVOL0.05×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsMar 3 · in 4mo
Dilution
Imugene Limited logoOTC:IUGNFClosed$0.0290-22.77%
Historical Data
DateOpenHighLowCloseVolume
Nov 13, 20260.02900.02900.02900.0290588
Nov 12, 20260.03760.03760.03760.03762,680
Nov 9, 20260.02540.03900.02000.03907,269
Nov 3, 20260.02390.02390.02310.023840,429
Oct 29, 20260.03500.06180.03500.061824,541
Oct 28, 20260.04130.04130.04130.04134,411
Oct 26, 20260.06000.06000.06000.06002,000
Oct 16, 20260.02000.05790.02000.0579931
Oct 15, 20260.03720.03720.03720.0372692
Oct 13, 20260.04150.04150.02000.0200421
Oct 12, 20260.03720.03720.03000.03002,381
Oct 9, 20260.02640.02640.01000.0100394
Oct 8, 20260.02830.03710.02830.0300916
Oct 7, 20260.01530.06850.01530.0432108,941
Oct 6, 20260.02780.02780.01700.017015,002
Oct 2, 20260.01890.04700.01890.025040,000
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies.

Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths.

The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers. This treatment operates by stimulating a broad polyclonal antibody response against HER2/neu receptors, specifically addressing gastric and breast cancers. Currently, HER-Vaxx is undergoing Phase 1b/2 clinical evaluation for its application in gastric cancer. Beyond its lead product, Imugene is also advancing PD1-Vaxx, another cancer vaccine designed to induce the body to generate polyclonal antibodies that block PD-1 signaling.

Additionally, they are developing CF33, a potent oncolytic virus constructed from a unique combination of genomic sequences sourced from various vaccinia virus strains. Imugene has forged a research collaboration with Celularity Inc. to integrate its CD19 oncolytic virus technology with Celularity's CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19, for the treatment of solid tumors. Furthermore, the company maintains a strategic partnership with Eureka Therapeutics, Inc. Established in 1986, Imugene Limited is headquartered in Sydney, Australia.

Key Metrics
Market Cap$15.94M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 549.58M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryAUAU
IPO Date-
Shares Outstanding549.58M
Authorized Shares
Float312.07M
52-Week Range
$0.0100$0.2950
$0.0290(7th percentile)
Volume
Average Daily Volume11.70K
588 today vs 11.70K avg(-95%)

30d Avg

11.70K

60d Avg

30.14K

90d Avg

38.66K

Earnings
Dividend History
No dividend history available

Imugene Limited (OTC: IUGNF) traded at $0.0290 on Nov 13, 2026, down 22.77% from the previous close of $0.0376. 52-week range: $0.0100 to $0.2950. The company is in the Healthcare sector (Biotechnology).